Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes
Bandaranayake T, Radcliffe C, Cvercko M, Golden M, Hao R. Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes. JAC-Antimicrobial Resistance 2024, 6: dlae174. PMID: 39493938, PMCID: PMC11524893, DOI: 10.1093/jacamr/dlae174.Peer-Reviewed Original ResearchDose of oritavancinInfective endocarditisTreatment of acute bacterial skinBacterial infectionsLipoglycopeptide antibacterial agentTertiary care medical centreAcute bacterial skinGram-positive bacterial infectionsInvasive bacterial infectionsTreatment failure rateNinety-five adult patientsSoft tissue infectionsProsthetic joint infectionGram-positive organismsBacterial skinDrug discontinuationTissue infectionsRetrospective studyAdult patientsClinical outcomesAdverse eventsOritavancinOff-labelJoint infectionTreat infections